Clinical Laboratory of Xuanwu Hospital, Capital Medical University, Beijing, 100053, People's Republic of China.
Clinical Laboratory of Xuanwu Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, 100053, People's Republic of China.
Alzheimers Res Ther. 2022 Jul 26;14(1):103. doi: 10.1186/s13195-022-01050-3.
The deposition of β-amyloid (Aβ) in the brain plays a major role in the pathogenesis of Alzheimer's disease (AD). Aβ is generated via amyloid precursor protein (APP) cleavage through the amyloidogenic pathway. In this pathway, β-secretase (BACE1) is the first and rate-limiting enzyme. Its expression increases through an unknown mechanism in patients with AD. Thus, the key regulatory mechanism of BACE1 in the AD process should be revealed to understand the pathogenesis of AD and explore the key treatment targets of AD.
Here, APPswe/PS1dE9 (APP/PS1) mice were employed to observe the Krüppel-like factor 5 (KLF5) and BACE1 levels in the serum and brain tissues. HT22 cells were used to explore the relationship between KLF5 and BACE1.
In this study, KLF5 was found to be a novel transcription factor that positively regulated BACE1 by binding to the BACE1 promoter. The KLF5 levels significantly increased not only in the CSF and serum of patients with AD but also in the brain tissue of APP/PS1 mice. They were closely related to cognitive capacity. KLF5 accelerated APP amyloidogenic metabolism and promoted Aβ synthesis through BACE1. Silencing BACE1 could block the KLF5-induced amyloidogenic process of APP. ML264 ameliorated the cognitive deficits and slowed down APP amyloidogenic cleavage in APP/PS1 mice.
The findings above suggest that upregulation of KLF5 might be a critical element in AD progression by accelerating BACE1-mediated APP amyloidogenic cleavage. The inhibition of KLF5 or the combined inhibitory effect of KLF5 and the BACE1 promoter might be a potential strategy to prevent AD pathogenesis.
β-淀粉样蛋白(Aβ)在大脑中的沉积在阿尔茨海默病(AD)的发病机制中起主要作用。Aβ 通过淀粉样前体蛋白(APP)通过淀粉样蛋白生成途径切割产生。在该途径中,β-分泌酶(BACE1)是第一个也是限速酶。其表达通过 AD 患者未知的机制增加。因此,应揭示 BACE1 在 AD 过程中的关键调节机制,以了解 AD 的发病机制并探索 AD 的关键治疗靶点。
在这里,使用 APPswe/PS1dE9(APP/PS1)小鼠观察血清和脑组织中 Krüppel 样因子 5(KLF5)和 BACE1 水平。HT22 细胞用于探索 KLF5 和 BACE1 之间的关系。
在这项研究中,发现 KLF5 是一种通过与 BACE1 启动子结合而正向调节 BACE1 的新型转录因子。不仅在 AD 患者的 CSF 和血清中,而且在 APP/PS1 小鼠的脑组织中,KLF5 水平均显着增加。它们与认知能力密切相关。KLF5 通过 BACE1 加速 APP 淀粉样代谢并促进 Aβ 合成。沉默 BACE1 可以阻止 KLF5 诱导的 APP 淀粉样形成过程。ML264 改善了 APP/PS1 小鼠的认知缺陷并减缓了 APP 淀粉样切割。
上述发现表明,通过加速 BACE1 介导的 APP 淀粉样蛋白切割,KLF5 的上调可能是 AD 进展的关键因素。抑制 KLF5 或 KLF5 和 BACE1 启动子的联合抑制作用可能是预防 AD 发病机制的潜在策略。